Dr. Mark Kris on Immunotherapy and Frontline Options for Patients With NSCLC

Mark Kris on New Therapies for Lung CancerПодробнее

Mark Kris, MD: Choosing a Treatment in NSCLCПодробнее

Dr. Mark G. Kris on Side Effects Management with ImmunotherapiesПодробнее

Immunotherapy in the Frontline and as Part of Combinations for NSCLCПодробнее

Dr. Kris on Adjuvant Systemic Therapy in NSCLCПодробнее

Mark Kris, MD: Lacking Actionable Mutations in NSCLCПодробнее

Dr. Kris on Combination Chemotherapy Approaches in NSCLCПодробнее

Dr. Kris on the Future of Immunotherapy and Targeted Therapy in Lung CancerПодробнее

Dr. Costin on Frontline Immunotherapy for Patients With NSCLCПодробнее

Selecting a Frontline Regimen for Nondriver NSCLCПодробнее

The Role of Immunotherapy in Metastatic NSCLCПодробнее

Dr. Kris on Personalizing Therapy in Lung CancerПодробнее

Dr Mark G. Kris on Use of the Patient’s GenomeПодробнее

Dr. Kris on Sequencing Challenges in Lung CancerПодробнее

Dr. Herbst on the Impact of Frontline Immunotherapy in Lung CancerПодробнее

Advice for Treating Patients With Lung CancerПодробнее

Dr. Kris Discusses Patient Acceptance of Mutation TestingПодробнее

Late-Stage Trials: Immunotherapy Combinations for NSCLCПодробнее

Dr. Mark Kris on the Combination of Molecularly Targeted TherapiesПодробнее